Deborah Faye
Zinzino-asiakas
Tervetuloa! Minulla on hienoja kokemuksia tuotteistani, ja uskon, että sinäkin tulet ihastumaan niihin. Kerro minulle, mitä mieltä olet!
Investor relations
Financial calendar
Zinzino Interim report Q3 2024
Zinzino Delårsrapport Q3 2024
Zinzino Bokslutskommuniké 2024
Zinzino Year-End Report 2024
Annualreport 2024
Årsredovisning 2024
Financial reports
Press releases
ZINZINO AB (PUBL): Share subscription due to directed set-off issues
torstai 19. syyskuuta 2024 15.30
AvaaZINZINO AB (PUBL.): ZINZINO ACQUIRES 49% OF CYPRIOT OLIVE OIL PRODUCER CLEANTHI ALPHA-OLENIC LTD
torstai 27. kesäkuuta 2024 11.00
AvaaZINZINO AB (PUBL): LETTER OF INTENT TO ACQUIRE ZURVITA INCREASES DISTRIBUTION POWER IN NORTH AMERICA
maanantai 17. kesäkuuta 2024 11.00
AvaaZINZINO AB (PUBL): Zinzino announces Serbia as next step in its global expansion
tiistai 11. kesäkuuta 2024 15.30
AvaaZINZINO AB (PUBL): Zinzino now seeks acquisitions in the US and Asia to increase distribution power
perjantai 7. kesäkuuta 2024 12.00
AvaaZINZINO AB (PUBL): Announcement from the annual general meeting
maanantai 27. toukokuuta 2024 16.30
AvaaZINZINO AB (PUBL): Zinzino acquires assets in Xelliss – strategic reinforcement in southern Europe and in the microalgae spirulina
sunnuntai 12. toukokuuta 2024 13.00
AvaaZINZINO AB (PUBL): NOTICE OF ANNUAL GENERAL MEETING IN ZINZINO AB ON MAY 27, 2024
perjantai 26. huhtikuuta 2024 8.00
AvaaZINZINO AB (PUBL): Zinzino and ACN, enter a strategic partnership in Europe, and in connection with it Zinzino carries out a directed new issue of B shares for SEK 10.4 million.
maanantai 29. tammikuuta 2024 10.00
AvaaZINZINO AB (PUBL): Zinzino changes Certified Adviser to Carnegie Investment Bank AB (publ)
torstai 30. marraskuuta 2023 9.00
AvaaZINZINO AB (PUBL): Zinzino announces Mexico as next step in its global expansion
perjantai 22. syyskuuta 2023 8.00
AvaaZINZINO AB (PUBL): Announcement from the annual general meeting
keskiviikko 31. toukokuuta 2023 16.20
AvaaZINZINO AB (PUBL.): NOTICE TO THE ANNUAL MEETING OF ZINZINO AB ON MAY 31, 2023
tiistai 2. toukokuuta 2023 8.00
AvaaZinzino AB (publ.) cancels warrants that have not been exercised
tiistai 2. toukokuuta 2023 8.00
AvaaZINZINO AB (PUBL): Zinzino launches Turkey as a next market on their road towards global expansion
tiistai 7. maaliskuuta 2023 14.30
AvaaThe stock
Sustainability Report
Read more about our sustainability approach, targets and 2023 performance.
Greta Billing
shares@zinzino.com
+46 73 627 17 54
Fredrik Nielsen
shares@zinzino.com
+46 (0)707 900 174
Certified Adviser
All companies whose shares are to be traded on the Nasdaq First North Premier Growth Market have a certified adviser who guides and supports the company through the listing process. Subsequently, the adviser monitors that the company complies with First North's regulations for providing information to the market and investors. Carnegie Investment Bank AB (publ) is the Certified Adviser for Zinzino AB.
Certified Adviser:
The Company’s Certified Adviser is Carnegie Investment Bank AB (publ)
Phone: +46 (0)73 856 42 65
E-mail: certifiedadviser@carnegie.se
Why invest in Zinzino
A clear global strategy with a growth-driven, future-proof business model
Zinzino is one of Europe’s fastest-growing direct sales companies with an aggressive global expansion strategy. The Scandinavian-based health tech company is currently operating in Europe, North America, Asia, Australia, India and Africa. The overall company strategy and business model is to achieve profitable growth in new as well as existing markets. The massive growth momentum of the past decade is expected to stay constant thanks to the stability and structure of the business model in combination with top-of-the-line digital market tools as well as continuous company acquisitions.
Help improve the health of the world
Our product concept is to give health back to the world. Our goal is to get the best out of people with enthusiasm, encouragement and a great deal of energy. We are the most customer-focused direct sales company in the world. Our most important product concept, Balance, is showing continued good growth and we currently have over 500,000 test results based on blood tests in our database. We are the company that has done the most fatty acid analyses in the world.
Product development at the leading edge
Through efficient product development in-house, the company has developed a number of new products in health in which it owns its own important intellectual property rights. The newly developed products are manufactured in our own efficient production facility which means that we have 100% quality control. Zinzino’s strategy in the coming years includes continued product development at the leading edge.
Strong market position and distribution
Zinzino has strong sales organisations in its principal markets with good relationships with its customer base. The broad product portfolio attracts new customer groups and thereby generates growth. Through an updated IT platform and logistics system, Zinzino is well equipped for the expected sales growth in the coming years.
Attractive cash flow enables increased stock dividends and gives a good direct return
Zinzino’s business has a very strong cash-generating capability. Effective management of working capital combined with investments that quickly generate revenue and marginal improvements generate a strong cash flow. Thus, dividends can be distributed in accordance with the target of at least 50 per cent of the free cash flow.
Jaa tämä sivu
Tai kopioi linkki